Interleukin-8 synthesis

"Interleukin‑8 synthesis" refers to the cellular processes leading to production and secretion of interleukin‐⁠⁠⁠⁠⁠⁠⁸ ⁠(IL–⁸), also known as chemokine C-X-C motif ligand ⁸ (CXCL⁸). This chemokine is produced primarily by macrophages, epithelial cells, endothelial cells, and other cell types in response to pro-inflammatory stimuli such as TNF-alpha, LPS, viral infection, and other cytokines. Synthesis involves activation of intracellular signaling cascades—such as MAPK/ERK/NF-kB—that drive transcription from the CXCL⁸ gene locus followed by translation into precursor peptide forms that are processed into active secreted isoforms. Increased interleukin–⁸ production plays key roles in neutrophil recruitment during acute inflammation but also contributes pathologically in chronic inflammatory diseases and cancer progression through effects on angiogenesis and tumor cell migration.[2][4][6] **In summary:** “Interleukin–⁸ synthesis” describes a regulated biological pathway/process—not an individual druggable molecular entity—and should be replaced with more precise targets like “C-X-C chemokine receptor type 1” (*CXCR1*) or “C-X-C chemokine ligand ⁸” (*CXCL₈/IL–₈*) when seeking structured information about therapeutic targeting.[1][5]

Other names

IL-8 productionCXCL8 expression

Mechanisms by which drugs may affect interleukin‑8 synthesis include: - Inhibition of pro-inflammatory transcription factors such as NF-kB - Modulation of upstream cytokines that induce IL‑8 gene expression (e.g., TNF-alpha inhibitors) (These mechanisms act on pathways regulating gene transcription rather than on an individual molecular target.)